Chronic HBV Drug Development Summit
New this year, the Chronic HBV Drug Development Summit is comprehensively addressing (more than ever before) the industry’s key challenges all the way from bench to bedside, ensuring therapeutics fulfil their true potential.
With over 292 million people living with a chronic infection and up to 80,000 Americans becoming newly infected with hepatitis B each year and more than 2 million Americans are chronically infected, the growing clinical need for AMD requires new interventions.
This meeting will be the centerpoint for exploring a broad variety of therapeutic modalities for the treatment of chronic hepatitis B infection from siRNA, Capsid Inhibitors, nucleic acid polymers and more.
From discovery up to clinical trials, this conference will delve into the challenges that have obstructed the development of chronic HBV therapeutics at all stages.
Alongside your peers you have the opportunity to hear from and interact with 19+ thought leaders in our expert speaker faculty, have access to 10+ hours of content exploring the latest advances in the chronic HBV field, form meaningful and long-lasting connections in the multiple and varied virtual networking sessions built into the event.
An Interactive Online Experience
We have created the virtual summit to satisfy the industry’s need to share cutting-edge research, learn from your peers and engage in quality networking within a niche and highly selective audience to forge valuable collaborations.
Live Q&As with
Ask your burning
questions directly to
our expert speakers in real-time, just as you would at a physical conference
Join smaller, informal group chats or video calls designed to spark crucial conversations around key challenges for the industry
5+ Hours of Networking
breaks will allow you
to connect 1-2-1 with
other attendees and
kick start critical
Content Available Post-Event
On conclusion of the
will be made available
to attendees where